Skip to main content
PREDILIFE logo

PREDILIFE — Investor Relations & Filings

Ticker · ALPRE ISIN · FR0010169920 LEI · 9695006IK5NBKHQU9116 PA Human health and social work activities
Open in API
Filings indexed 150 across all filing types
Latest filing 2024-04-30 AGM Information
Country FR France
Listing PA ALPRE

About PREDILIFE

https://www.predilife.com/en/

PREDILIFE specializes in predictive medicine, developing solutions to assess an individual's risk of developing major diseases. The company's approach integrates medical data, such as genetic testing and imaging, with artificial intelligence and mathematical models to create personalized risk profiles. Its primary offerings are predictive health check-ups, including a specialized test for assessing the 5-year risk of breast cancer (MammoRisk®) and a multi-condition check-up that evaluates the risk for several common cancers (lung, prostate, colorectal, melanoma) and cardiovascular disease. Based on these risk profiles, PREDILIFE provides personalized follow-up and preventive recommendations. The company offers its end-to-end solution, which includes remote consultations, to businesses, insurers, and healthcare professionals to facilitate wider access to preventive care.

Recent filings

Filing Released Lang Actions
RÉSULTATS DE L'ASSEMBLÉE GÉNÉRALE ORDINAIRE ET EXTRAORDINAIRE DE PREDILIFE
AGM Information Classification · 1% confidence The document is explicitly titled "RÉSULTATS DE L'ASSEMBLÉE GÉNÉRALE ORDINAIRE ET EXTRAORDINAIRE DE PREDILIFE" (Results of the Ordinary and Extraordinary General Meeting of PREDILIFE) and details the outcomes of the shareholder meeting held on April 29, 2024. It lists resolutions that were adopted, such as the approval of annual accounts, renewal of director mandates, and authorizations for capital changes. This content directly relates to the official results from a general meeting. Therefore, the appropriate classification is AGM-R (AGM Information), as it reports the results and key decisions made during the AGM.
2024-04-30 French
Valorisation du logiciel MammoRisk(R)
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE 25 AVRIL 2024" (Press Release April 25, 2024) and announces the valuation of the MammoRisk® software, providing a specific monetary range (€191.7 M to €223.3 M). This is a formal announcement of a significant business event (asset valuation for potential licensing) released to the public via a press release format. It is not a full annual report (10-K), an interim report (IR), or a transcript (CT). Since it is a specific announcement regarding business/financial strategy (valuation for licensing), it fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if no other category fits well. Given that the core subject is the valuation of an asset intended to facilitate future licensing/financing discussions, CAP is a strong candidate. However, press releases announcing specific, non-standard financial metrics or strategic updates often fall into the general Regulatory Filings category (RNS) if they don't strictly match ER, DIV, or CAP. Since this is a valuation announcement, which is a key piece of information for investors but not a standard financial report, RNS (Regulatory Filings / Miscellaneous Announcement) is the most appropriate general classification for a press release of this nature that doesn't detail earnings or dividends. The document length (5045 chars) is substantial enough that it is the report itself, not just an announcement of a report (RPA). I will classify it as RNS as it is a general regulatory/investor communication.
2024-04-25 French
Valuation of MammoRisk(R) software
Regulatory Filings Classification · 1% confidence The document is explicitly titled as a "PRESS RELEASE" dated April 25, 2024. It announces the valuation of the company's MammoRisk® software, determined by an external expert (SORGEM Evaluation), resulting in a determined value range (€191.7 million to €223.3 million). This is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a formal regulatory filing like a proxy statement. It is an announcement regarding a specific corporate event/assessment that impacts potential future financing or licensing. Since it is a press release announcing a significant corporate development (valuation), and it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director's Dealing (DIRS), the most appropriate general category for a significant, non-standard corporate announcement is Regulatory Filings (RNS), which serves as a broad category for official company news releases that don't fit elsewhere, or potentially a Capital/Financing Update (CAP) if the valuation is directly tied to immediate fundraising, but RNS is safer for a general valuation announcement press release. Given the options, RNS (Regulatory Filings) is the best fit for a general press release announcing a valuation assessment, as it is a standard form of corporate disclosure not covered by the more specific financial report codes.
2024-04-25 English
MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2023
Report Publication Announcement Classification · 1% confidence The document is a press release dated April 24, 2024, titled "MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2023" (Making available of the 2023 Annual Financial Report). It explicitly states that the annual financial report for the year ended December 31, 2023, has been made available to the public and filed with the AMF, and directs readers to the company website to find it. Since the document itself is an announcement about the availability of the full report, and not the report itself, it fits the definition of a Report Publication Announcement (RPA). The document length (1450 chars) is very short, supporting the 'MENU VS MEAL' rule.
2024-04-24 French
RÉSULTATS ANNUELS 2023 - PROGRESSION DES VENTES AUX ENTREPRISES ET SUCCÈS DU RECRUTEMENT DES PATIENTES DANS L'ÉTUDE CLINIQUE EUROPÉENNE
Earnings Release Classification · 1% confidence The document is explicitly titled "RÉSULTATS ANNUELS 2023" (Annual Results 2023) and contains a detailed table summarizing key financial figures for 2023 compared to 2022, including revenue, operating result, and net result. This strongly indicates a primary financial reporting document covering a full fiscal year. However, the final section states: "Le rapport financier annuel au 31 décembre 2023, intégrant le rapport de gestion, les comptes annuels et consolidés 2023 ainsi que les rapports des commissaires aux comptes sur lesdits comptes, sera mis à disposition du public au plus tard le 30 avril 2022." (Note: The date '2022' seems like a typo for '2024' given the context of 2023 results being announced on March 28, 2024, but the key is that it announces the *future availability* of the full Annual Financial Report). The document itself is a press release summarizing the annual results, which aligns best with an Earnings Release (ER) or a Management Discussion and Analysis (MDA) summary, as it provides key highlights and management commentary before the full statutory report is released. Given the comprehensive nature of the financial summary provided (including the table and discussion of results), it goes beyond a simple ER. Since it discusses the full year's results and includes detailed financial figures, it functions as the primary disclosure of the annual performance. In many contexts, the press release accompanying the finalization of annual accounts is classified as the Earnings Release (ER) or, if it contains significant management analysis, MDA. Since it details the full year's performance and the board approval date, it is the primary disclosure of the annual results. If the full statutory report (10-K equivalent) were attached, it would be 10-K. Since this is the announcement summarizing the results, ER is the most appropriate fit among the options, although MDA is also plausible due to the commentary. Given the structure focusing on 'Résultats Annuels 2023' and the financial table, ER is selected as the initial release of the annual performance data. FY 2023
2024-03-28 French
L'Unédic offre à ses employés un bilan prédictif multi-pathologies
Environmental & Social Information Classification · 1% confidence The document is titled 'COMMUNIQUÉ DE PRESSE' (Press Release) dated March 7, 2024, announcing a partnership between PREDILIFE and Unédic regarding health screening for Unédic employees. This is a general corporate announcement regarding a business development, not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a press release announcing a business event, and it does not fit into the more specific categories like M&A (TAR), Capital Change (CAP), or Director's Dealing (DIRS), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory or significant corporate announcements that aren't covered elsewhere. Given the context of a press release, RNS is the most appropriate general classification.
2024-03-07 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.